Kamada Ltd
KMDAKamada Ltd (KMDA) is an Israel-based biopharmaceutical company specializing in the development, manufacturing, and commercialization of plasma-derived protein therapeutics for the treatment of various medical conditions, such as rare diseases and inflammatory disorders. The company's products are based on plasma proteins, including Alpha-1 antitrypsin, used for treatment and research purposes. Kamada leverages its proprietary manufacturing platform to produce plasma-derived therapies and expand its portfolio in the biopharmaceutical space.
Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| April 7, 2025 | $0.20 | 2025-03-17 | 2025-03-17 |
Dividends Summary
- Kamada Ltd has issued 1 dividend payments over the past 0 years
- The most recent dividend was paid 245 days ago, on April 7, 2025
- The highest dividend payed out to investors during this period was $0.20 per share
- The average dividend paid during this period was $0.20 per share.
Company News
Kamada reported strong financial performance in Q3 2025, with revenues of $47.0 million (up 13% year-over-year) and adjusted EBITDA of $11.7 million (up 34%). The company reiterated its full-year revenue guidance of $178-$182 million and continues to focus on business development and plasma collection operations.
Gainers ParaZero Technologies Ltd. (NASDAQ: PRZO) shares jumped 106% to $2.3901 after the company announced an Australian regulator approved first commercial drone flights in populated areas and near people using ParaZero safety systems. HUB Cyber Security Ltd. (NASDAQ: HUBC) shares jumped 60.5% to $0.3836. Phoenix Motor Inc. (NASDAQ: PEV) climb...
Shares of Israeli pharmaceutical giant Teva are down Monday following Hamas's attack over the weekend.
Zymeworks (ZYME) recently entered a collaboration with Jazz Pharmaceuticals (JAZZ) for its lead pipeline candidate. This has been a significant catalyst for the stock.
